Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: FLUARIX QUADRIVALENT; Biological
Lead sponsor: Emory University; Other
Eligibility: 42 Years to 71 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Influenza VLP Vaccine (recombinant), Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more

Conditions: Healthy or Stable Underlying Chronic Medical Condition
Interventions: Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 18
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 15 more

Conditions: Influenza, Human
Interventions: Viral changes, Protect others, General intentions, Behavioral intentions, Accountability; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 7,206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Severe Combined Immunodeficiency
Interventions: unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion, unrelated PBSC with T cell depletion; Biological · Device
Lead sponsor: Neena Kapoor, M.D.; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Avian Influenza
Interventions: H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Durham, North Carolina • Nashville, Tennessee • Houston, Texas

Conditions: Influenza, Healthy Volunteers
Interventions: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more

Conditions: Influenza
Interventions: Vaccine administration by a pharmacist, Unmet vaccination needs identified and met, Vaccination forecast review and patient education; Biological · Behavioral
Lead sponsor: American Pharmacists Association Foundation; Other
Eligibility: 18 Years and older
Enrollment: 6,234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Atlantic, Iowa • Carlisle, Iowa • Coralville, Iowa + 18 more

Conditions: Fever
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 23 Months
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Pregnancy, Influenza
Interventions: Oseltamivir (Tamiflu), Blood Draws; Drug · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza, Human
Interventions: Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3., Flu Pandemic mRNA_ Dose level 4, Flu Pandemic mRNA_Dose level 5, Flu Pandemic mRNA_Dose level 6, Influenza virus vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 991 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Anniston, Alabama • Little Rock, Arkansas • Fort Collins, Colorado + 18 more

Conditions: Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions: Fluzone High Dose Vaccine, Standard of care/Placebo; Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
Interventions: Osteopathic manipulation, Sham; Other
Lead sponsor: Lake Erie College of Osteopathic Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Influenza
Interventions: VAX2012Q, Fluzone Quadrivalent; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Influenza
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Probiotic- Bifidobacterium Bifidum, Sugar Pill, Probiotic- Lactobacillus helveticus, Probiotic- Bifidobacterium longum ss. Infantis R0033; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 583 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Prostate Adenocarcinoma
Interventions: Positron Emission Tomography, Lymphadenectomy, Radiation Therapy, Abiraterone Acetate, Prednisone, Computed Tomography, Abiraterone, PSMA PET Scan; Procedure · Radiation · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2037
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Influenza, Human
Interventions: PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine plus Fludarabine and Busulfan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Healthy Participants
Interventions: Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo; Biological · Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 49 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: INO-3605, INO-3609, INO-3401, INO-3605 AND INO-3609, INO-3510, Seasonal Influenza vaccine; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Overland Park, Kansas • Baltimore, Maryland

Conditions: HIV Infections
Interventions: Autologous Dendritic Cell HIV Vaccination; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Comparative Tests of Flu Vaccination Phone Messages

SCID Bu/Flu/ATG Study With T Cell Depletion

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

PRO#0118: Decitabine Plus Mini Flu-Bu

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs